Inhibition of extracellular signal-regulated kinase 1/2 signaling has beneficial effects on skeletal muscle in a mouse model of Emery-Dreifuss muscular dystrophy caused by lamin A/C gene mutation

Antoine Muchir\(^1,2,3\)*, Young Jin Kim\(^1,2,4\), Sarah A Reilly\(^1,2,5\), Wei Wu\(^1,2\), Jason C Choi\(^1,2\) and Howard J Worman\(^1,2\)*

**Abstract**

**Background:** Autosomal Emery-Dreifuss muscular dystrophy is caused by mutations in the lamin A/C gene (LMNA) encoding A-type nuclear lamins, intermediate filament proteins of the nuclear envelope. Classically, the disease manifests as scapulo-humeroperoneal muscle wasting and weakness, early joint contractures and dilated cardiomyopathy with conduction block; however, more variable skeletal muscle involvement can be present. Previously, we demonstrated increased activity of extracellular signal-regulated kinase (ERK) 1/2 in hearts of Lmna\(^{H222P/H222P}\) mice, a model of autosomal Emery-Dreifuss muscular dystrophy, and that blocking its activation improved cardiac function. We therefore examined the role of ERK1/2 activity in skeletal muscle pathology.

**Methods:** Sections of skeletal muscle from Lmna\(^{H222P/H222P}\) mice were stained with hematoxylin and eosin and histological analysis performed using light microscopy. ERK1/2 activity was assessed in mouse tissue and cultured cells by immunoblotting and real-time polymerase chain reaction to measure expression of downstream target genes. Lmna\(^{H222P/H222P}\) mice were treated with selumetinib, which blocks mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 that activates ERK1/2, from 16 to 20 weeks of age to assess the effects of treatment on muscle histology, ERK1/2 activity and limb grip strength.

**Results:** We detected enhanced activation of ERK1/2 in skeletal muscle of Lmna\(^{H222P/H222P}\) mice. Treatment with selumetinib ameliorated skeletal muscle histopathology and reduced serum creatine phosphokinase and aspartate aminotransferase activities. Selumetinib treatment also improved muscle function as assessed by in vivo grip strength testing.

**Conclusions:** Our results show that ERK1/2 plays a role in the development of skeletal muscle pathology in Lmna\(^{H222P/H222P}\) mice. They further provide the first evidence that a small molecule drug may be beneficial for skeletal muscle in autosomal Emery-Dreifuss muscular dystrophy.

**Keywords:** Muscular dystrophy, Nuclear envelope, Lamin, Selumetinib, Mitogen-activated protein kinase
Background

Emery-Dreifuss muscular dystrophy (EDMD) is classically characterized clinically by a triad of: (1) slowly progressive muscle weakness and wasting in a scapulo-humeroperoneal distribution; (2) early contractures of the elbows, ankles, and posterior neck; and (3) dilated cardiomyopathy with conduction defects [1,2]. Contractures are usually the first clinical sign of the disease occurring in the first decade of life. During the second decade of life, the slowly progressive muscle weakness and wasting typically begin. At the end of the second decade, most patients develop evidence of cardiomyopathy [3-5].

EDMD can be inherited in a X-linked or autosomal fashion. X-linked EDMD is caused by mutations in EMD encoding emerin [6]. Emerin is an integral protein of the inner nuclear membrane [7,8]. The majority of autosomal dominant and less frequent recessive cases are caused by mutations in LMNA [9,10]. LMNA encodes two major somatic cell polypeptides, lamin A and lamin C, which are components of the nuclear lamina, a meshwork of intermediate filaments on the inner aspect of the inner nuclear membrane [11-14]. While the classical EDMD phenotype was first attributed to EMD and LMNA mutations, it is now apparent that the same mutations in these genes can cause dilated cardiomyopathy with more variable skeletal muscle involvement [6,9,15-21]. Intriguingly, LMNA mutations (different than those leading to myopathy) can also cause partial lipodystrophy, peripheral neuropathy, or accelerated aging disorders such as Hutchinson-Gilford progeria syndrome [22].

Despite the relatively recent advances in understanding the genetics of EDMD and related myopathies, the pathogenic mechanisms leading to striated muscle damage are only poorly understood. One useful small animal model to study pathogenesis and evaluate potential therapeutic interventions in autosomal EDMD is the Lmna$^{H222P/H222P}$ mouse [23]. Starting at approximately 16 weeks, male Lmna$^{H222P/H222P}$ develop progressive dystrophic pathology in several skeletal muscle groups. Later, they have progressive accumulation of connective tissue in skeletal muscle. Lmna$^{H222P/H222P}$ mice also develop dilated cardiomyopathy with conduction system abnormalities and significant cardiac fibrosis.

We have previously shown that Lmna$^{H222P/H222P}$ mice have increased activity of the mitogen-activated protein kinase extracellular signal-regulated kinase (ERK) 1/2 in cardiac muscle [24]. This increased ERK1/2 activity occurs prior to the onset of overt tissue pathology, suggesting that it plays a primary pathogenic role. Treatment of Lmna$^{H222P/H222P}$ mice with drugs that inhibit mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK) 1/2, the kinase that activates ERK1/2, have increased activity of the mitogen-activated protein kinase extracellular signal-regulated kinase (ERK) 1/2 in cardiac muscle [24]. This increased ERK1/2 activity occurs prior to the onset of overt tissue pathology, suggesting that it plays a primary pathogenic role. Treatment of Lmna$^{H222P/H222P}$ mice with drugs that inhibit mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK) 1/2, the kinase that activates ERK1/2, leads to improved left ventricular ejection fraction [25,26], decreased cardiac fibrosis [26,27] and prolonged survival [27]. While these results strongly suggest that abnormal ERK1/2 activation contributes to the development of cardiomyopathy in Lmna$^{H222P/H222P}$ mice, its pathogenic role in affected skeletal muscles is unknown.

Based on our findings in heart, we hypothesize that abnormal activation of ERK1/2 is similarly involved in the pathogenesis of skeletal muscular dystrophy in the Lmna$^{H222P/H222P}$ mouse model of EDMD. In the present study, we demonstrate increased activation of ERK1/2 in affected skeletal muscle these mice. We further show that treatment with the MEK1/2 inhibitor selumetinib ameliorates pathological changes and improves function. These results suggest that MEK1/2 inhibitors may be beneficial in treating both cardiac and skeletal muscle disease in patients with EDMD.

Methods

Mice

Lmna$^{H222P/H222P}$ mice were bred and genotyped as previously described [23]. Mice were fed chow and housed in a disease-free barrier facility with 12 h/12 h light/dark cycles. The Institutional Animal Care and Use Committee at Columbia University Medical Center approved the use of animals and the study protocols.

Drug treatment protocol and harvesting of muscle samples

Selumetinib (Selleck Chemicals) was dissolved in dimethyl sulfoxide (DMSO) (Sigma) at a concentration of 0.5 mg/mL to allow for intraperitoneal injections in mice. The placebo control consisted of the same volume of DMSO. Selumetinib was delivered at a dose of 1 mg/kg daily by intraperitoneal injection using a 27 5/8-gauge syringe starting when mice were 16 weeks of age and continuing until 20 weeks of age. At the end of the study, mice were sacrificed and hindlimb and diaphragm muscles dissected. Part of each dissected muscle was frozen in liquid nitrogen and stored at -80°C for biochemical analysis. The remaining muscle was rapidly frozen in isopentane pre-chilled by liquid nitrogen for cryostat sectioning.

Histology

Frozen pieces of quadriceps femoris, diaphragm, and tibialis anterior were mounted in Tissue-Tek (Fisher Scientific) and 10 μm sections cut on a cryostat. Sections were stained with hematoxylin and eosin for histological analysis. Representative sections were photographed using a Microphot SA (Nikon) light microscope attached to a Spot RT Slide camera (Diagnostic Instruments). Images were processed using Adobe Photoshop CS (Adobe Systems).

Osmotic shock of C2C12 cells stably expression wild-type and H222P lamin A

Generation of stable C2C12 cells expressing wild-type and H222P lamin A has been described previously [28].
These cells were maintained at 37°C with 5% CO$_2$ and subcultured at approximately 60% to 70% confluence in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum (Invitrogen). To assess the impact of osmotic shock on the activation of ERK1/2, cells were treated with D-sorbitol (600 mM) for 1 h and proteins were harvested in RIPA extraction buffer (Cell Signaling Technology) as previously described [24].

Quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was extracted using the RNeasy isolation kit (Qiagen). Total RNA was used to synthesize cDNA using SuperScript First-strand Synthesis System (Invitrogen) according to the manufacturer’s instructions. For each replicate in each experiment, RNA from tissue samples of different animals was used. Primers were designed corresponding to mouse RNA sequences using Primer3 [29]. Real-time quantitative RT-PCR reactions contained HotStart-IT SYBR green qPCR Master Mix (Affymetrix), 200 nM of each primer and 0.2 μL of template in a reaction volume of 25 μL. Amplification was carried out using the ABI 7300 Real-time PCR System (Applied Biosystems). Relative levels of mRNA expression were calculated using the ΔΔCT method [30] and individual expression values were normalized by comparison to Gapdh mRNA.

Protein extraction and immunoblotting
Skeletal muscle was homogenized in RIPA extraction buffer (Cell Signaling Technology) as previously described [24]. Extracted proteins were separated by SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose membranes, and blotted with primary antibodies against ERK1/2 and phosphorylated ERK1/2 (Cell Signaling Technology). Secondary antibodies were horse-radish peroxidase-conjugated (GE Healthcare). Recognized proteins were visualized by enhanced chemiluminescence (GE Healthcare). To quantify results, the immunoblots were scanned and band densities calculated using ImageJ64 (Applied Imaging). Signals obtained for phosphorylated ERK1/2 were normalized to those for total ERK1/2.
Serum biochemistry
Serum was separated from mouse blood and stored at -80°C for 3 to 9 months until analyzed. Creatine phosphokinase (CPK) and aspartate aminotransferase (AST) activities were measured using an Analyst III Analyzer (Hemagen Diagnostics) in the Comparative Pathology Laboratory at Columbia University Medical Center. CPK and AST activities have been shown to be stable in rodent serum stored for up to 360 days at -70°C [31].

Limb grip strength measurements
*Lmna*<sup>H222P/H222P</sup> mice treated with DMSO or selumetinib were subjected to limb grip strength testing using a horizontally positioned grip strength meter (Bioseb). Mice were lowered by the tail towards the grid on the apparatus. Upon grasping the grid with their limbs, mice were pulled backward in the horizontal plane. The procedure was repeated consecutively three times and the peak tension of the three pulls was recorded as the grip strength value. Each animal was subjected to a total of two serial trials of three pulls each with 20 s of rest in between.

Statistics
Values for real-time quantitative RT-PCR, scanned immunoblots, internalized nuclei, serum CPK and AST activities, and grip strength were compared using an unpaired Student t-tests. Values for Feret’s diameter were compared using two-way ANOVA. Statistical
analyses were performed using Prism (GraphPad Software).

Results and discussion

Dystrophic skeletal muscle pathology in Lmna<sup>H222P/H222P</sup> mice

Arimura et al. [23] previously reported progressive dystrophic changes in skeletal muscle starting at 16 weeks male Lmna<sup>H222P/H222P</sup> mice. Their non-quantitative histopathological analysis included descriptions of a wide variation in fiber size, an increased number of atrophic, hypertrophic, and lobulated fibers, some regenerative fibers and a mention that some fibers had internalized nuclei. We therefore carefully quantified myofiber diameters and internalized nuclei in histological sections of quadriceps, diaphragm, and tibialis anterior muscle of male wild-type and Lmna<sup>H222P/H222P</sup> mice at 20 weeks of age. Compared to wild-type mice, quadriceps and tibialis anterior from the Lmna<sup>H222P/H222P</sup> mice exhibited a wider variation in fiber size (Figure 1A). In quadriceps, there was a clear shift towards smaller fiber diameters, consistent with the presence of greater numbers of atrophic and regenerative fibers. Both of these muscle groups also had an increased percentage of fibers with internal nuclei, which is observed during regeneration (Figure 1A,B). At this age, however, diaphragm did not show significant differences between Lmna<sup>H222P/H222P</sup> and wild-type mice (Figure 1A,B).

Abnormal ERK1/2 signaling in skeletal muscle of Lmna<sup>H222P/H222P</sup> mice

Hearts of Lmna<sup>H222P/H222P</sup> mice and human subjects with autosomal EDMD have increased activity of ERK1/2, which likely plays a role in pathogenesis of cardiomyopathy [24-27]. We hypothesized that a similar increased activation of this signaling pathway occurs in skeletal muscle. We therefore examined ERK1/2 activity in skeletal muscle from 20-week-old male Lmna<sup>H222P/H222P</sup> mice. Immunoblotting with antibody against phosphorylated (activated) ERK1/2 demonstrated a two-fold increase in activity in quadriceps of Lmna<sup>H222P/H222P</sup> mice compared to wild type mice (Figure 2A). We then used quantitative real-time PCR to measure expression of downstream ERK1/2 target genes, several of which are members of the ETS family of transcription factors that are phosphorylated by ERK1/2 and positively autoregulate their transcriptional activity [24,32,33]. Of 11 targets genes assessed, we detected significantly increased expression of mRNAs...
for nine in quadriceps, six in diaphragm, and seven in tibialis anterior of Lmna^{H222P/H222P} mice compared to wild-type controls (Figure 2B). Among these, Mef-2, Elk1, Atf2, Atf4, and Nfatc-4 showed significantly increased expression in the three skeletal muscles examined. These data demonstrate that ERK1/2 is hyperactivated in the skeletal muscles of Lmna^{H222P/H222P} mice. Increased ERK1/2 activation in diaphragm at an age before there is any detectable histological abnormalities is consistent with its increased activity in heart prior to the onset of detectable pathological signs of cardiomyopathy [24]. This suggests that increased ERK1/2 signaling is involved in the pathogenesis of dystrophic skeletal muscle pathology.

Stress-induced activation of ERK1/2 in cultured myoblasts stably expressing H222P lamin A

We have previously shown that transient transfection of C2C12 mouse myoblasts with cDNA encoding H222P prelamin A or other variants associated with striated muscle disease have increased ERK1/2 activity compared to those transfected with a cDNA encoding wild-type prelamin A [24]. However, stably transfected C2C12 cells expressing H222P lamin A do not have increased ERK1/2 activity at baseline but do after glucose deprivation or treatment with 5-aminoimidazole-4-carboxamide ribonucleoside [28]. This led us to hypothesize that physiological stress, such as that associated with manipulations necessary for transient transfection or induced by altered energy metabolism, is necessary to increase ERK1/2 activity in myoblasts expressing lamin A variants. We further tested this hypothesis by subjecting the same cells stably expressing lamin A H222P that do not have baseline elevation in ERK1/2 [28] to osmotic shock. One hour after an osmotic shock with 600 mM D-sorbitol, cells expressing flag-tagged H222P lamin A had a greater activity of ERK1/2 compared to those expressing flag-tagged wild-type lamin A (Figure 3). This result provided additional support for a model in which alterations in the nuclear lamina associated with striated muscle disease lead to abnormalities in the activities of cellular stress-responsive signaling pathways [24,34,35]. The requirement of a stress to hyperactivate ERK1/2 in cells expressing the H222P lamin A may also at least in part explain why striated muscle, a tissue repeatedly under mechanical strain, is preferentially affected by Lmna mutations generating certain A-type lamin variants.

Blocking ERK1/2 activity with selumetinib has beneficial effects on skeletal muscle in Lmna^{H222P/H222P} mice

Given the enhanced ERK1/2 activity in skeletal muscle of Lmna^{H222P/H222P} mice that develop muscular dystrophy, we hypothesized that it may contribute to pathology. To test this hypothesis, we set up experiments to determine if inhibiting ERK1/2 signaling would prevent the progression of muscular dystrophy. At 16 weeks of age, ERK1/2 activity was elevated in quadriceps muscle of Lmna^{H222P/H222P} mice compared to wild-type mice, as assessed by immunoblotting with antibody against phosphorylated kinase (Figure 4).

We administered the MEK1/2 inhibitor selumetinib to male Lmna^{H222P/H222P} mice by giving daily intraperitoneal injections (1 mg/kg) starting at 16 weeks of age. After 4 weeks of treatment, the mice had reduced phosphorylated ERK1/2 in quadriceps, tibialis anterior, and diaphragm compared to placebo-treated mice. This demonstrated that systemically administered selumetinib inhibited ERK1/2 signaling in skeletal muscle (Figure 5).
Figure 6 (See legend on next page.)
Following 4 weeks of treatment with selumetinib, there was significantly reduced expression of embryonic myosin heavy chain (Myh3) mRNA in quadriceps, diaphragm, and tibialis anterior of Lmna\(^{H222P/H222P}\) mice (Figure 6A). This represented a partial reversal of embryonic myosin expression that typically occurs in dystrophic muscle [36,37]. While quadriceps from DMSO-treated mice had 0.52% fibers (4/772 from three mice) with internalized nuclei (Figure 6A, arrows), there were none detected in 571 fibers from three mice in the selumetinib-treated mice (and 1/604 fibers from three wild-type mice as shown in Figure 1B). DMSO treatment did not impact myofiber diameter compared to untreated Lmna\(^{H222P/H222P}\) mice; however, mice treated with selumetinib had a greater myofiber diameter in quadriceps compared to those treated with DMSO (Figure 6B). Between 16 and 20 weeks of age, there was a significant increase in serum CPK activity in Lmna\(^{H222P/H222P}\) mice treated with DMSO; however, CPK activity did not significantly increase in the mice that received selumetinib and at 20 weeks it was significantly lower than in those that received DMSO (Figure 6C). Mean serum AST activity was also significantly lower in the selumetinib-treated mice compared to the placebo-treated mice at 20 weeks of age (data not shown). To determine if selumetinib improved skeletal muscle function in Lmna\(^{H222P/H222P}\) mice, we evaluated grip strength. At 20 weeks of age, mean grip strength was significantly greater in selumetinib-treated Lmna\(^{H222P/H222P}\) mice than in DMSO-treated mice (Figure 6D). Hence, selumetinib improved skeletal muscle dystrophic pathology and improved function in Lmna\(^{H222P/H222P}\) mice.

Conclusions

We have shown increased activity of ERK1/2 in skeletal muscle of the Lmna\(^{H222P/H222P}\) mouse model of autosomal EDMD and that blocking its activity ameliorates pathology. These results are in accordance with a growing body of research providing evidence that alterations in various cellular signaling pathways, including ERK1/2, are involved in the pathogenesis of muscular dystrophy [38]. In addition to autosomal EDMD, ERK1/2 has been implicated as contributing to skeletal or cardiac muscle pathology in mdx [39-41], \(\gamma\)-sarcoglycan-deficient [42,43], and Lmna\(^{292P}\) mouse, respective small animal models of Duchenne, limb girdle type 2C, and a form of congenital muscular dystrophy. ERK1/2 activity is also abnormally increased in hearts of mice with emerin deficiency, which is the genetic alteration in X-linked EDMD [45].

Blocking increased ERK1/2 signaling activity with selumetinib had beneficial effects on skeletal muscle function in Lmna\(^{H222P/H222P}\) mice. Previously, we obtained similar results with respect to the cardiomyopathy that occurs in these mice [24-27]. In a human clinical trial, selumetinib has been reported to promote muscle gain in patients with cholangiocarcinoma [46]. As oral selumetinib and other orally bioavailable MEK1/2 inhibitors with encouraging safety profiles are currently in clinical development for other indications [47,48], pilot trials in patients with EDMD and possibly other muscular dystrophies should be considered.

Abbreviations

AST: Aspartate aminotransferase; CPK: Creatine phosphokinase; DMSO: Dimethyl sulfoxide; EDMD: Emery-Dreifuss muscular dystrophy; ERK: Extracellular signal-regulated kinase; Lmna: Lamins A/C gene; MEK: Mitogen-activated protein kinase/extracellular signal-regulated kinase kinase; RT-PCR: Reverse transcription-polymerase chain reaction.

Competing interests

AM and HJW are inventors on a pending patent application (PCT/US09/42614) on methods for treating and/or preventing cardiomyopathies by ERK and JNK inhibition filed by the Trustees of Columbia University in the City of New York.

Authors’ contributions

AM conceived of the study, bred mice, treated mice with drugs, carried out experiments measuring ERK1/2 activity in mouse tissue and cells, assessed skeletal muscle pathology and grip strength in mice, and drafted the manuscript. YJK carried out experiments on measuring ERK1/2 activity in mouse tissue and cells and assessing skeletal muscle pathology in mice. SAR assisted with isolating skeletal muscle from mice and participated in experiments measuring ERK1/2 activity in mouse tissue. WW bred mice, drew blood from mice, and assisted in treating mice with drugs. JCC generated stable cell lines expressing H222P and wild type lamin A. HJW helped conceive the study, supervised and coordinated all of the research, and wrote the final manuscript. All of the authors read and approved the final manuscript.
References
1. Emery AEH, Dreffus FE: Unusual type of benign X-linked muscular
dystrophy. J Neurol Neurosurg Psychiat 1966, 29:338–342.
2. Emery AE: X-linked muscular dystrophy with early contractures and
cardiomyopathy (Emery-Dreffus type). Clin Genet 1967, 3:360–367.
3. Waters DD, Nutter DO, Hopkins LC, Dorney ER: The c-ets-1 proto-oncogene has oncogenic activity and
is positively autoregulated. J Biol Chem 2000, 275:1407–1412.
4. Lin F, Worman HJ: Mitogen-activated protein kinase inhibitors improve heart function and prevent fibrosis in cardiomyopathy
cause by mutations in the lamin A/C gene. Circ Res 2008, 103:1459–1465.
5. Muchir A, Bonne G, van der Kooi AJ, van Tintelen JP, Bonne G, Merlini L, Schwartz K: Identification of mutations in the gene encoding
lamin A/C in autosomal dominant limb girdle muscular dystrophy with atroventricular conduction disturbances (LGMDB11), Hum Mol Genet 2000, 
9:1453–1459.
6. Muchir A, Bonne G, van der Kooi AJ, van Tintelen JP, Bonne G, Merlini L, Schwartz K: Activation of MAPK pathways links LMNA mutations to cardiomyopathy in
Emery-Dreffus muscular dystrophy. J Clin Invest 2007, 117:282–293.
7. Muchir A, Shapira D, Sosna V, Lehnart SE, Worman HJ: Mouse model carrying H222P-Lmna mutation develops muscular dystrophy and dilated cardiomyopathy similar to human striated muscle laminopathies. Hum Mol Genet 2005, 14:155–166.
8. Muchir A, Moro S, Gamba V, Cavallini I, Ponzoni M, Bencardino JT, Cassano F, De Girolami U, Seidman JG, Seidman C, Muntoni F: Treatment with selumetinib preserves cardiac function and improves survival in cardiomyopathy caused by mutation in lamin A/C gene. Circulation 2012, 125:254–269.
9. Muchir A, Shapira D, Sosna V, Lehnart SE, Worman HJ: Suppression of extracellular signal-regulated kinase signaling in human striated muscle laminopathies. Hum Mol Genet 2005, 14:155–166.
10. Muchir A, Shapira D, Sosna V, Lehnart SE, Worman HJ: Suppression of extracellular signal-regulated kinase signaling in human striated muscle laminopathies. Hum Mol Genet 2005, 14:155–166.
34. Lammerding J, Schulze PC, Takahashi T, Kozlov S, Sullivan T, Kamme RD, Stewart CL, Lee RT: Lamina A/C deficiency causes defective nuclear mechanics and mechanotransduction. J Clin Invest 2004, 113:370–378.
35. Dauer WT, Worman HJ: The nuclear envelope as a signaling node in development and disease. Dev Cell 2009, 17:626–638.
36. Chen YW, Zhao P, Borup R, Hoffman EP: Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology. J Cell Biol 2000, 151:1321–1336.
37. Haslett JN, Sanoudou D, Kho AT, Bennett RR, Greenberg SA, Kohane IS, Beggs AH, Kunkel LM: Gene expression comparison of biopsies from Duchenne muscular dystrophy (DMD) and normal skeletal muscle. Proc Natl Acad Sci USA 2002, 99:15000–15005.
38. Burks TN, Cohn RD: Role of TGF-β signaling in inherited and acquired myopathies. Skeletal Muscle 2011, 1:19.
39. Kumar A, Khandelwal N, Malaya R, Reid MB, Boriek AM: Loss of dystrophin causes aberrant mechanotransduction in skeletal muscle fibers. FASEB J 2004, 18:102–113.
40. Lang JM, Esser KA, Dupont-Versteegden EE: Altered activity of signaling pathways in diaphragm and tibialis anterior muscle of dystrophic mice. Exp Biol Med 2004, 229:503–511.
41. Smythe GM, Forwood JK: Altered mitogen-activated protein kinase signaling in dystrophic (mdx) muscle. Muscle Nerve 2012, 46:374–383.
42. Griffin MA, Feng H, Tewari M, Acosta P, Kawai M, Sweeney HJ, Disher DE: γ-sarcoglycan deficiency increases cell contractility, apoptosis and MAPK pathway activation but does not affect adhesion. J Cell Sci 2005, 118:1405–1416.
43. Barton ER: Impact of sarcoglycan complex on mechanical signal transduction in murine skeletal muscle. Am J Physiol Cell Physiol 2006, 290:C411–C419.
44. Kumar A, Yanaiuchi J, Girgenrath T, Girgenrath M: Muscle-specific expression of insulin-like growth factor 1 improves outcome in Lama2Dy-w mice, a model for congenital muscular dystrophy type 1A. Hum Mol Genet 2011, 20:2333–2343.
45. Muchir A, Pavlidis P, Bonne G, Hayashi YK, Worman HJ: Activation of MAPK in hearts of EMD null mice: similarities between mouse models of X-linked and autosomal dominant Emery Dreifuss muscular dystrophy. Hum Mol Genet 2007, 16:1884–1893.
46. Prado CM, Bekaii-Saab T, Doyle LA, Shrestha S, Ghosh S, Baraco VE, Sawyer MB: Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma. Br J Cancer 2012, 106:1583–15836.
47. Chapman MS, Miner JN: Novel mitogen-activated protein kinase kinase inhibitors. Expert Opin Investig Drugs 2011, 20:209–220.
48. Trujillo JJ: MEK inhibitors: a patent review 2008–2010. Expert Opin Ther Pat 2011, 21:1045–1069.

doi:10.1186/2044-5040-3-17
Cite this article as: Muchir et al.: Inhibition of extracellular signal-regulated kinase 1/2 signaling has beneficial effects on skeletal muscle in a mouse model of Emery-Dreifuss muscular dystrophy caused by lamin A/C gene mutation. Skeletal Muscle 2013 3:17.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit